Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Immunogenicity of CMAB807 vs Prolia in Healthy Chinese Males
NCT03925051Phase 1Completed
- Sponsor
- Shanghai Biomabs Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMAB807 in osteoporosis (2 arms), sponsored by Shanghai Biomabs Pharmaceuticals. Primary endpoints: Area Under the Serum Concentration-Time Curve from Time 0 to Time t and Maximum Serum Concentration. Started Jul 2019; status: completed.
02
Drugs
CMAB807
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03925051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925051.